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Abstract SH2 domain containing phosphatase-2 (SHP-2) has
an important regulatory role in a variety of cell types. However,
little is known concerning its function in platelets. We show here
that, in thrombin-stimulated human platelets, SHP-2 undergoes
a time-dependent association with platelet endothelial cell
adhesion molecule-1 (PECAM-1) and four low molecular weight
phosphoproteins which are attenuated by the Src kinase inhibitor
PP1. The low molecular weight proteins, which may be
transmembrane proteins, are shown to bind exclusively to the
N-terminal SH2 domain of SHP-2 and are therefore possible
activators of the phosphatase. In addition, SHP-2 phosphatase
activity is shown to be increased following thrombin stimulation
or cross-linking of PECAM.
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1. Introduction
SH2 domain containing phosphatase-2 (SHP-2) (also
known as SH-PTP2, PTP1D, Syp or PTP2C) is a ubiquitously
expressed 68 kDa non-receptor protein tyrosine phosphatase
comprising two N-terminal tandem SH2 domains linked to a
C-terminal catalytic phosphatase domain with a C-terminal
tail [1,2]. It belongs to a family of SH2 domain containing
protein tyrosine phosphatases which includes SHP-1 and the
Drosophila homologue of SHP-2, Corkscrew [3,4]. However,
unlike SHP-1, which is largely restricted to haematopoietic
cells and appears to have a de¢ned negative role in cellular
signalling [5,6], the expression of SHP-2 is ubiquitous and its
function remains unclear. Attempts to produce SHP-2 knock-
out mice strains resulted in day 9.5 embryonic lethality due to
severe suppression of haematopoietic cell development [7,8].
In vitro studies using both overexpression and dominant neg-
ative techniques, however, have indicated both positive and
negative regulatory roles for SHP-2. In support of a positive
signalling role, SHP-2 has been shown to associate with
growth factor receptors [9], cytokine receptors [10] and adhe-
sion molecules [11], ligation of which can lead to MAP kinase
activation, cellular growth and di¡erentiation [12,13]. A neg-
ative regulatory role for SHP-2 was proposed following the
observation by Myers that insulin receptor signalling was en-
hanced following inhibition of SHP-2 association with the
insulin receptor substrate, implying that SHP-2 normally at-
tenuates this pathway [14]. In addition, SHP-2 has recently
been shown to attenuate T-cell activation by dephosphorylat-
ing the j-chain of the T-cell receptor [15]. Thus, it appears
that the role of SHP-2 may alter depending upon the cell type
and the nature of the associating proteins.
Recent structural analysis of SHP-2 [16] showed it to be
activated by binding of tyrosine-phosphorylated proteins to
the N-terminal SH2 domain, causing exposure of the active
catalytic phosphatase site. It was proposed that the C-termi-
nal SH2 domain plays a role to stabilise associations made by
the N-terminal SH2 domain, since the a⁄nity of interaction
between two SH2 domains and a binding partner has been
shown to be much greater than the sum of the a⁄nities of the
individual SH2 domains for their binding partners [17]. Iden-
ti¢cation of tyrosine phosphoproteins which bind SHP-2 is
therefore important since they may represent activators or
substrates of the phosphatase. Recent studies have shown
that a number of adaptor proteins associate with SHP-2 after
receptor activation. These include Grb-2 [18^20], SHPS-1 [21],
SIT [22], PZR [23] and the FcOR L-chain [24]. Whilst these
adaptor proteins have no enzymatic function, they are be-
lieved to link surface receptors to intracellular signalling path-
ways. Thus, the association of SHP-2 with the L-subunit of
the interleukin-3 receptor [10] and the insulin receptor [25]
may involve the formation of a protein complex with several
tyrosine-phosphorylated adaptor proteins. However, whether
association with these adaptor proteins can activate SHP-2
has not yet been demonstrated.
The only SHP-2 binding protein reported to date in human
platelets is platelet endothelial cell adhesion molecule-1 (PE-
CAM-1) [26], a 130 kDa glycoprotein expressed on the surface
of platelets and endothelial cells where it localises to cell-cell
borders and mediates leukocyte transmigration and platelet
adhesion [27]. PECAM-1 is a member of the immunoglobulin
(Ig) superfamily comprising six extracellular Ig like domains,
a single transmembrane region and a long cytoplasmic tail
[28]. Studies in platelets have shown that following aggrega-
tion, two of the ¢ve tyrosine residues in the cytoplasmic tail of
PECAM-1 become phosphorylated, facilitating an association
between PECAM-1 and the SH2 domains of SHP-2 [29]. It
has not been shown, however, whether this association causes
the activation of SHP-2 or the triggering of a signal trans-
duction pathway leading to a functional response.
To further understand the role of SHP-2 in platelets, we
have sought to identify and characterise tyrosine-phosphoryl-
ated proteins which associate with SHP-2 under a variety of
activating conditions. Using thrombin-stimulated human plat-
elets, we have identi¢ed a novel set of tyrosine-phosphorylated
0014-5793 / 99 / $20.00 ß 1999 Federation of European Biochemical Societies. All rights reserved.
PII: S 0 0 1 4 - 5 7 9 3 ( 9 9 ) 0 1 2 0 9 - 0
*Corresponding author. Fax: (44) (117) 925 0168.
E-mail: c.edmead@bristol.ac.uk
Abbreviations: SHP-2, SH2 domain containing phosphatase-2; PE-
CAM-1, platelet endothelial cell adhesion molecule-1; WGA, wheat
germ agglutinin
FEBS 22650 22-9-99
FEBS 22650 FEBS Letters 459 (1999) 27^32
SHP-2 associating proteins, at least two of which bind the
N-terminal SH2 domain of SHP-2 and can therefore be con-
sidered as putative activators of SHP-2. In addition, we have
shown that both thrombin and PECAM-1 can stimulate SHP-
2 phosphatase activity in the absence of SHP-2 phosphoryl-
ation.
2. Materials and methods
2.1. Materials
Antibodies were purchased from Santa Cruz (Autogen Bioclear,
Devizes, Wiltshire, UK) with the exception of anti-phosphotyrosine
monoclonal antibody 4G10 which was obtained from Upstate Bio-
technology (TCS Biologicals, Bucks, UK). AB468, a mouse mono-
clonal anti-PECAM-1 antibody directed against the extracellular
portion of the molecule, was used for cross-linking and immunopre-
cipitation of PECAM whilst a goat polyclonal anti-PECAM antibody
(sc1505), directed against the cytoplasmic tail, was used for blotting.
The full length SHP-2 and GST-N+C-SH2 constructs were kindly
donated by Dr. Steven Shoelson (Harvard Med. School, Boston,
USA). The Src family kinase inhibitor PP1 was from Alexis Corpo-
ration (Nottingham, UK). The in vitro tyrosine phosphatase assay kit
was from Promega (Southampton, UK). Acrylamide/bisacrylamide
solution was from National Diagnostics (Hull, UK). All other re-
agents were purchased from Sigma (Poole, Dorset, UK).
2.2. Preparation of human platelets
Citrated venous blood samples were collected from healthy volun-
teers not currently taking medication. Platelet-rich plasma was sepa-
rated by centrifugation (180Ug, 20 min) and PGE1 (40 ng/ml) was
added to prevent activation of the platelets during preparation. A
platelet pellet was obtained from a second centrifugation (800Ug,
10 min) and resuspended in modi¢ed tyrodes-HEPES solution
(145 mM NaCl, 2.9 mM KCl, 10 mM HEPES, 1 mM MgCl2, 5 mM
glucose, pH 7.3) to a density of 1U109 platelets/ml with indomethacin
(10 WM) to block eicosanoid production. Platelets were rested for
30 min at 30‡C prior to use.
2.3. Construction of GST fusion proteins
PCR primers containing EcoRI and NotI restriction sites were de-
signed and used to amplify the single SH2 domains from a full length
SHP-2 template. Following puri¢cation and digestion, the SH2 frag-
ments were re-ligated into pGEX-4T-2 and transformed into Esche-
richia coli bacteria. All PCR product sequences were checked before
use and primer sequences are available on request. The GST fusion
proteins were induced with IPTG and bound to glutathione beads for
use in immunoprecipitation assays. For dephosphorylation assays, the
puri¢ed fusion protein was eluted from the beads with excess gluta-
thione (5 mM).
2.4. Platelet activation, immunoprecipitation and Western blotting
350 Wl aliquots of PRP were placed in an aggregometer tube and
stirred (800 rpm) at 37‡C. Appropriate agonists or inhibitors were
added at the concentrations and for the duration stated in Section
3. Stimulation was always carried out in the presence of EGTA
(1 mM) and was terminated by the addition of an equal volume of
2UNP-40 lysis bu¡er (2% (v/v) NP-40, 300 mM NaCl, 20 mM Tris,
1 mM PMSF, 10 mM EDTA, 2 mM Na3VO4, 10 Wg/ml leupeptin,
10 Wg/ml aprotinin, 1 Wg/ml pepstatin A, pH 7.3). The tubes were
vortexed to ensure complete solubilisation of the platelet proteins
prior to centrifugation to pellet insoluble material. For immunopreci-
pitations, the supernatant was pre-cleared with protein A-Sepharose
for 1 h at 4‡C prior to the addition of primary antibody. Immuno-
precipitations and GST fusion protein precipitations were carried out
for 2 h at 4‡C after which time the beads were pelleted by centrifu-
gation, washed three times in TBS-T bu¡er and resuspended in an
equal volume of 2ULaemmli sample bu¡er. Samples were separated
on 5^15% polyacrylamide slab gels under reducing conditions, trans-
ferred to PVDF membranes and blotted with appropriate antibodies.
Membranes were incubated for 60 min at room temperature with
primary antibodies, followed by secondary antibodies and bands
were detected using ECL reagent (Amersham) and exposure of the
blot to photographic ¢lm.
2.5. Digestion of transmembrane proteins
Following thrombin stimulation, platelets were incubated at 37‡C
for 10 min in the presence or absence of trypsin (0.6 mg/ml) and
chymotrypsin (25 Wg/ml). The digestion was terminated by the addi-
tion of PMSF (2.5 mM) prior to lysis of the platelets.
2.6. In vitro phosphatase assay
SHP-2 immunoprecipitates were prepared from resting and stimu-
lated platelets, washed three times in TBS-T and once in phosphate-
free water before resuspension in assay bu¡er (25 mM Na-acetate pH
5, 20% glycerol, 1 mM DTT, 1 mM EDTA). The samples were then
added to a 96 well plate containing tyrosine-phosphorylated peptide
substrate. Following a 30 min incubation at 30‡C, the reaction was
terminated by the addition of molybdenate dye solution. Phosphatase
activity was assessed by a spectrophotometric assay of released free
phosphate.
2.7. Dephosphorylation assays
The ability of SHP-2 to speci¢cally dephosphorylate endogenous
substrates was tested by incubating SHP-2 immunoprecipitates in de-
phosphorylation bu¡er alone (150 mM NaCl, 50 mM Tris pH 7.4,
5 mM DTT) or in the presence of 10 Wg of puri¢ed GST-SHP-2
proteins at 37‡C for the speci¢ed time. To control for dissociation,
the assay was repeated in the presence of vanadate to inhibit phos-
phatase activity. Samples were then pelleted, resuspended in sample
bu¡er and analysed by gel electrophoresis.
3. Results
3.1. SHP-2 associates with tyrosine-phosphorylated proteins in
thrombin-activated platelets
To identify possible tyrosine-phosphorylated proteins which
associate with SHP-2, we immunoprecipitated SHP-2 from
resting platelets and from platelets stimulated with thrombin
(1 U/ml) for various time periods (Fig. 1). In resting platelets,
a low level of constitutive association of three tyrosine-phos-
phorylated proteins of approximately 127, 33 and 29 kDa
with SHP-2 was observed. Following thrombin stimulation
for 15 s, however, a signi¢cant increase in the association of
all three proteins was demonstrated. In addition, a further two
Fig. 1. SHP-2 associates with several tyrosine-phosphorylated pro-
teins in human platelets. SHP-2 immunoprecipitations were carried
out on platelets stimulated with thrombin for the time shown before
sodium dodecyl sulfate-polyacrylamide gel electrophoresis (SDS-
PAGE) analysis and immunoblotting with anti-phosphotyrosine
antibody, 4G10. The positions of PECAM-1, SHP-2 and the four
low molecular weight associating proteins are shown.
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tyrosine-phosphorylated proteins were seen at 31 and 27 kDa.
Under these conditions, SHP-2 itself does not become tyro-
sine-phosphorylated. The association of all ¢ve proteins was
maximal by 60 s with a decline in the intensity of the lower
bands after this timepoint. By 10 min, the 31 and 27 kDa
bands were no longer detectable and by 30 min, all associa-
tions had returned to basal levels (data not shown).
3.2. Tyrosine-phosphorylated PECAM-1 associates with
SHP-2
In accordance with previous reports, PECAM-1 was de-
tected in SHP-2 immunoprecipitates from platelets stimulated
with thrombin (1 U/ml, 1 min) (Fig. 2A) and coincided with
the tyrosine-phosphorylated 127 kDa band seen on 4G10
blots. However, the amount of PECAM detected in SHP-2
immunoprecipitations did not correlate with the amount of
tyrosine-phosphorylated protein observed on 4G10 blots. To
con¢rm whether PECAM was the sole constituent of pp127,
platelets were incubated with trypsin and chymotrypsin fol-
lowing thrombin stimulation to digest extracellular proteins.
Under these conditions, PECAM-1 was almost completely
digested and most prominently to a protein of 90 kDa. Com-
parison of the digestion pattern of PECAM in whole cell
lysates (Fig. 2B (i)) and pp127 in SHP-2 immunoprecipitates
(Fig. 2B (ii) overexposed so as to show all digestion products)
showed that whilst a small component of pp127 digested sim-
ilarly to PECAM, the appearance of a digestion product at 65
kDa suggested that SHP-2 also associates with another pro-
tein or proteins in thrombin-stimulated platelets which co-mi-
grate with PECAM-1 at 127 kDa. In addition, there appeared
to be a decrease in the intensity of the low molecular weight
associating proteins following trypsin digestion, indicating
that they also may be transmembrane proteins. This was par-
ticularly marked for pp33 and pp31, although the e¡ect on
pp29 and pp27 was di⁄cult to assess due to possible overlap
with a PECAM digestion fragment.
3.3. Phosphorylation of the low molecular weight proteins is
dependent upon Src family kinases
Cao [30] has previously reported that the kinase responsible
for the phosphorylation of PECAM-1 on tyrosine residues
663 and 686 may be a member of the Csk or Src family of
protein tyrosine kinases. We decided to investigate the role of
Src kinases in the phosphorylation of the low molecular
weight proteins using the Src family kinase inhibitor PP1.
Pre-incubation of platelets with PP1 (10 WM) prior to throm-
bin stimulation resulted in the disappearance of pp33, 31, 29
and 27 in association with SHP-2, indicating that their phos-
phorylation and/or association with SHP-2 is downstream of
Src kinases (Fig. 3).
3.4. The associating proteins bind di¡erentially to the SH2
domains of SHP-2
To establish the SHP-2 binding sites of the low molecular
weight proteins (pp33, 31, 29 and 27), we used GST fusion
proteins of the tandem (GST-NC-SH2) and single SH2 do-
mains (GST-N-SH2, GST-C-SH2) of SHP-2 in precipitation
experiments. Fig. 4 shows that whilst GST alone failed to
precipitate any tyrosine-phosphorylated proteins from throm-
bin-stimulated platelet lysates, GST-NC-SH2 precipitated all
Fig. 2. (A) PECAM-1 becomes phosphorylated and associates with
SHP-2 in thrombin-stimulated platelets. SHP-2 immunoprecipita-
tions were carried out on platelets stimulated with thrombin before
SDS-PAGE analysis and immunoblotting with anti-PECAM-1 (i).
Blots were stripped and re-probed with 4G10 (ii). (B) pp127 consists
of more than one protein. Thrombin- stimulated platelets were incu-
bated with trypsin and chymotrypsin for 10 min prior to SDS-
PAGE analysis. (i) Whole cell lysates immunoblotted for PECAM
(ii) SHP-2 immunoprecipitates immunoblotted for 4G10.
Fig. 3. Phosphorylation of the low molecular weight proteins is de-
pendent upon Src family kinases. Platelets were incubated with ty-
rodes or PP1 (10 WM) as indicated for 15 min prior to stimulation
with thrombin followed by SDS-PAGE analysis and immunoblot-
ting with 4G10.
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four of the low molecular weight phosphoproteins, indicating
that they all associate with SHP-2 via its SH2 domains. Im-
munoprecipitations using the single SH2 domain GST fusion
constructs revealed that pp29 and pp33 associated exclusively
with the N-terminal SH2 domain but that pp27 and pp31 did
not appear to bind to either of the single SH2 domains.
3.5. Cross-linking of PECAM-1 induces its phosphorylation
We assessed the ability of cross-linking PECAM-1, using
speci¢c antibodies, to induce phosphorylation of PECAM-1.
As can be seen in Fig. 5, whilst anti-PECAM-1 antibody
alone (1 Wg/ml, 5 min) had no e¡ect, after cross-linking using
a rabbit anti-mouse antibody (30 Wg/ml, 5 min) PECAM-1
became strongly phosphorylated. However, this did not ap-
pear to result in the induction or speci¢c interaction with any
other tyrosine-phosphorylated proteins (data not shown). Nei-
ther were we able to detect SHP-2 in PECAM-1 immunopre-
cipitations by immunoblotting, probably due to the small
fraction of total PECAM-1 which associates with SHP-2
(data not shown).
3.6. Thrombin and cross-linked PECAM-1 can activate SHP-2
Despite the failure of SHP-2 to become phosphorylated
following thrombin stimulation or PECAM-1 cross-linking,
the presence of associating proteins binding to the N-terminal
SH2 domain suggested that SHP-2 may be activated under
these conditions. We therefore carried out an in vitro phos-
phatase assay to assess SHP-2 activity in resting and stimu-
lated platelets. As shown in Fig. 6A, both thrombin and PE-
CAM-1 cross-linking caused a signi¢cant increase in SHP-2
phosphatase activity, as measured by release of free phosphate
from an exogenous tyrosine-phosphorylated peptide substrate.
3.7. The associating proteins are not substrates of SHP-2
Since we have demonstrated that thrombin could activate
SHP-2 in vitro, we decided to investigate whether the low
molecular weight proteins were also substrates of SHP-2. In-
cubation of SHP-2 immunoprecipitates in dephosphorylation
bu¡er resulted in a marked decrease in the intensity of the low
molecular weight bands. However, no further reduction was
observed in the presence of puri¢ed GST-SHP-2, neither was
the decrease inhibited by vanadate. This indicates that the
associating proteins are not SHP-2 substrates and that the
observed decrease in the intensity of the bands is due to dis-
sociation of the proteins during the time period of the experi-
ment.
Fig. 4. pp29 and pp33 associate exclusively with the N-SH2 domain of SHP-2. GST fusion proteins were used to immunoprecipitate lysates
from thrombin-stimulated platelets prior to SDS-PAGE analysis and immunoblotting with 4G10.
Fig. 5. Cross-linking of PECAM-1 causes its phosphorylation. Plate-
lets were stimulated with anti-PECAM or rabbit anti-mouse anti-
bodies alone or together for 5 min prior to SDS-PAGE analysis
and immunoblotting with 4G10.
Fig. 6. (A) Thrombin and cross-linked PECAM-1 can activate SHP-
2. SHP-2 immunoprecipitates from resting and stimulated platelets
were mixed with tyrosine-phosphorylated peptide substrate. Phos-
phatase activity was assessed by a spectrophotometric assay of re-
leased free phosphate. (B) The associating proteins are not sub-
strates of SHP-2. After washing, SHP-2 immunoprecipitates were
incubated with dephosphorylation bu¡er alone or in the presence of
GST-SHP-2 fusion protein for 1 h prior to SDS-PAGE analysis and
immunoblotting with 4G10.
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4. Discussion
The only SHP-2 associating phosphoprotein reported to
date in platelets is PECAM. We have further investigated
SHP-2 signalling in thrombin-stimulated platelets and demon-
strated an additional four low molecular weight proteins
which associate with SHP-2 in a time-dependent manner.
The trypsin digestion experiments indicated that these low
molecular weight proteins may be transmembrane proteins
and may therefore have a function either as receptors or as
adaptor molecules linking SHP-2 to surface receptors. Of the
known SHP-2 associating adaptor proteins, immunoblotting
has shown that they are not forms of Grb-2, whilst the mo-
lecular weight of SHPS-1 and PZR is too high. The recently
cloned SHP-2 binding protein SIT was a possible candidate,
but unlike SIT, the molecular weights of the proteins were
unaltered under non-reducing conditions (data not shown),
implying that they do not normally exist as dimers. Another
possible candidate was FcOR L-chain, which is known to be
present in platelets and exists in multiple forms due to di¡er-
ential splicing and phosphorylation states and is a substrate of
the Src kinase Lyn [31]. However, FcOR L-chain immunoblot-
ting failed to detect proteins in the SHP-2 immunoprecipitates
(data not shown).
Further investigations revealed that the phosphorylation of
pp27, 29, 31 and 33 is attenuated by PP1, indicating that the
phosphorylation step occurs downstream of Src family ki-
nases. PECAM-1 has previously been reported to bind to
and to be phosphorylated by a Src kinase [30,32] and Walter
has shown that SHP-2 can activate Src by a non-enzymatic
mechanism involving binding to the SH3 domain of the kinase
[33]. Furthermore, since it was shown that pp33 and pp29
bound exclusively to the N-terminal SH2 domain of SHP-2,
which is known to be an important regulatory site for SHP-2
activity, SHP-2 may recruit a Src family kinase to phospho-
rylate these proteins, which in turn associate with and activate
SHP-2. Platelets contain several di¡erent Src family kinases
and further studies will be required to establish the identity of
the speci¢c kinase responsible and its role in regulating the
phosphorylation and binding of the low molecular weight
proteins to SHP-2.
In agreement with previous studies by Jackson, we have
also demonstrated an association between tyrosine-phos-
phorylated PECAM-1 and SHP-2 in human platelets, which,
due to the absence of any other tyrosine-phosphorylated pro-
teins in PECAM-1 immunoprecipitations, appears to be a
direct interaction. However, in contrast to Jackson, we found
that this association was not dependent upon aggregation.
The di¡erence may be accounted for by the use of EGTA
instead of RGDS to dissociate the KIIbL3 receptor or by
the use of thrombin instead of TRAP to stimulate the plate-
lets. Indeed, we found that whilst stimulation of the platelets
with collagen also induced an association of PECAM-1 with
SHP-2, this association could be e¡ectively inhibited by the
addition of EGTA (data not shown), indicating that at least
some of the signalling pathways regulating the association of
PECAM with SHP-2 are aggregation-dependent. Further-
more, by comparison with thrombin, collagen (100 Wg/ml,
2 min) and WGA (10 Wg/ml, 2 min) also enhanced the asso-
ciation of pp29 and pp33 although neither agonist induced the
association of pp27 or pp31 (data not shown). Thus, the as-
sociation of some of the low molecular weight proteins with
SHP-2 is agonist-speci¢c.
Despite the high copy number of PECAM-1 in human
platelets, we could only detect small amounts of PECAM-1
associated with SHP-2. Furthermore, we were unable to detect
SHP-2 in PECAM immunoprecipitates, implying that only a
small proportion of available PECAM-1 associates with SHP-
2. This appears to contradict the appearance of a highly phos-
phorylated band at 127 kDa in SHP-2 immunoprecipitates
and whilst PECAM does become highly phosphorylated, we
provide evidence here that pp127 consists of more than one
protein. The studies involving trypsin/chymotrypsin digestion
of PECAM indicated that whilst pp127 contains PECAM-1,
the appearance of a digestion product at 65 kDa and the poor
appearance of the pp90 digestion product of PECAM-1 imply
the presence of a second 127 kDa transmembrane phospho-
protein which associates with SHP-2 in thrombin-stimulated
platelets.
Interestingly, despite activation of SHP-2 by thrombin and
cross-linking of PECAM-1, SHP-2 is not tyrosine-phosphoryl-
ated itself as in other cell types. This demonstrates that phos-
phorylation is not a requirement of SHP-2 activation, but
instead may enable interaction of SHP-2 with other SH2 con-
taining proteins to form signalling complexes.
In conclusion, we have reported and partially characterised
four novel low molecular weight phosphoproteins and suggest
the existence of a ¢fth which co-migrates with PECAM-1, all
of which, in addition to PECAM, associate with SHP-2 in
thrombin-stimulated platelets. Phosphorylation and associa-
tion of the low molecular weight proteins with SHP-2 is de-
pendent upon Src family kinase activity and the association is
mediated through the SH2 domains of SHP-2. Thrombin and
PECAM-1 can couple to activation of SHP-2 although the
low molecular weight associating proteins are not substrates
of the phosphatase. It will be important to identify the asso-
ciating proteins and to determine whether they mediate the
activation of SHP-2.
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